These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 34725356)

  • 1. Lessons Learned From Global Hepatitis C Elimination Programs.
    Handanagic S; Shadaker S; Drobeniuc J; Tsereteli M; Alkhazashvili M; Adesigbin C; Adamu I; Adabe R; Agwuocha C; Adisa O; Azania A; Boeke CE; Ngwije A; Serumondo J; Armstrong PA
    J Infect Dis; 2024 May; 229(Supplement_3):S334-S341. PubMed ID: 37739781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China].
    Liu PC; Xu D; Ding GW; Zhao L; Yu JJ; Liu ZF; Li J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Mar; 45(3):464-472. PubMed ID: 38514325
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
    Chaillon A; Wynn A; Kushner T; Reau N; Martin NK
    Clin Infect Dis; 2021 Nov; 73(9):e3355-e3357. PubMed ID: 32282879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Strategies to Identify Children with Perinatally Acquired Hepatitis C Infection.
    Hall EW; Panagiotakopoulos L; Wester C; Nelson N; Sandul AL
    J Pediatr; 2023 Jul; 258():113409. PubMed ID: 37023948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.
    Mitruka K; Tsertsvadze T; Butsashvili M; Gamkrelidze A; Sabelashvili P; Adamia E; Chokheli M; Drobeniuc J; Hagan L; Harris AM; Jiqia T; Kasradze A; Ko S; Qerashvili V; Sharvadze L; Tskhomelidze I; Kvaratskhelia V; Morgan J; Ward JW; Averhoff F
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(28):753-7. PubMed ID: 26203628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Considerations for Global Public Health Data Modernization: Lessons from Modernizing the Hepatitis C Program Data Analytics System in the Country of Georgia.
    Aniekwe C; Getia VK; Gvinjilia L; Manders EJ; Shadaker S; Schumacher IT; Mindadze M; Skhvitaridze N; Becknell S; Santas X
    J Public Health Manag Pract; 2024 Sep-Oct 01; 30(5):643-646. PubMed ID: 39041759
    [No Abstract]   [Full Text] [Related]  

  • 7. What Is Needed to Move Toward Single-Step Diagnosis of Current HCV Infection?
    Feld JJ
    J Infect Dis; 2024 May; 229(Supplement_3):S316-S321. PubMed ID: 37831406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.
    Snell G; Marshall AD; van Gennip J; Bonn M; Butler-McPhee J; Cooper CL; Kronfli N; Williams S; Bruneau J; Feld JJ; Janjua NZ; Klein M; Cunningham N; Grebely J; Bartlett SR
    Can Liver J; 2023 Jul; 6(2):190-200. PubMed ID: 37503523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality Assurance for Hepatitis C Virus Point-of-Care Diagnostics in Sub-Saharan Africa.
    Duah E; Mathebula EM; Mashamba-Thompson T
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
    PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
    John-Baptiste A; Yeung MW; Leung V; van der Velde G; Krahn M
    Pharmacoeconomics; 2012 Nov; 30(11):1015-34. PubMed ID: 23050771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator.
    Adee M; Zhuo Y; Zhong H; Zhan T; Aggarwal R; Shilton S; Chhatwal J
    Sci Rep; 2021 Nov; 11(1):21382. PubMed ID: 34725356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.
    Tskhomelidze I; Shadaker S; Kuchuloria T; Gvinjilia L; Butsashvili M; Nasrullah M; Gabunia T; Gamkrelidze A; Getia V; Sharvadze L; Tsertsvadze T; Zarqua J; Tsanava S; Handanagic S; Armstrong PA; Averhoff F; Vickerman P; Walker JG
    Liver Int; 2023 Mar; 43(3):558-568. PubMed ID: 36129625
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.